Curaleaf (OTCMKTS:CURLF – Get Free Report) and Haemonetics (NYSE:HAE – Get Free Report) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.
Earnings & Valuation
This table compares Curaleaf and Haemonetics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Curaleaf | $1.27 billion | 2.01 | -$231.07 million | ($0.13) | -28.00 |
| Haemonetics | $1.33 billion | 2.52 | $97.31 million | $2.02 | 36.68 |
Risk & Volatility
Curaleaf has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
Insider & Institutional Ownership
0.0% of Curaleaf shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Curaleaf and Haemonetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Curaleaf | -7.76% | -8.11% | -2.36% |
| Haemonetics | 7.29% | 27.30% | 9.59% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Curaleaf and Haemonetics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Curaleaf | 0 | 1 | 1 | 2 | 3.25 |
| Haemonetics | 1 | 3 | 6 | 1 | 2.64 |
Haemonetics has a consensus price target of $78.33, indicating a potential upside of 5.71%. Given Haemonetics’ higher possible upside, analysts clearly believe Haemonetics is more favorable than Curaleaf.
Summary
Haemonetics beats Curaleaf on 12 of the 15 factors compared between the two stocks.
About Curaleaf
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
About Haemonetics
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
